NASDAQ:DERM

Dermira Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$18.75
0.00 (0.00 %)
(As of 02/20/2020)
Add
Compare
Today's Range
$18.75
$18.75
50-Day Range
$18.73
$18.85
52-Week Range
$5.25
$19.48
VolumeN/A
Average Volume1.24 million shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.56

Receive DERM News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermira and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DERM
CUSIPN/A
Phone650-421-7200
Employees333
Year FoundedN/A

Sales & Book Value

Annual Sales$42.34 million
Book Value($0.21) per share

Profitability

Net Income$-221,540,000.00
Net Margins-256.08%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$1.02 billion
Next Earnings DateN/A
OptionableOptionable

Headlines

See More Headlines
Dermira logo

About Dermira

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.

MarketRank

Overall MarketRank

0.85 out of 5 stars

Medical Sector

1165th out of 2,041 stocks

Pharmaceutical Preparations Industry

516th out of 769 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Dermira (NASDAQ:DERM) Frequently Asked Questions

What stocks does MarketBeat like better than Dermira?

Wall Street analysts have given Dermira a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dermira wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Dermira's earnings last quarter?

Dermira Inc (NASDAQ:DERM) announced its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.40) by $0.34. The biopharmaceutical company had revenue of $11.53 million for the quarter, compared to the consensus estimate of $11.07 million. Dermira had a negative trailing twelve-month return on equity of 583.07% and a negative net margin of 256.08%.
View Dermira's earnings history
.

Who are Dermira's key executives?

Dermira's management team includes the following people:
  • Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 67)
  • Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 77)
  • Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 51)
  • Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 42)
  • Mr. Christopher M. Griffith, Co-Founder and Chief Bus. & Strategy Officer (Age 43)

Who are some of Dermira's key competitors?

What other stocks do shareholders of Dermira own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Novavax (NVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), Karyopharm Therapeutics (KPTI), Pfizer (PFE), AT&T (T), Exelixis (EXEL) and ImmunoGen (IMGN).

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

What is Dermira's stock price today?

One share of DERM stock can currently be purchased for approximately $18.75.

How much money does Dermira make?

Dermira has a market capitalization of $1.02 billion and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis.

How many employees does Dermira have?

Dermira employs 333 workers across the globe.

What is Dermira's official website?

The official website for Dermira is www.dermira.com.

Where are Dermira's headquarters?

Dermira is headquartered at 275 Middlefield Road Suite150, Menlo Park CA, 94025.

How can I contact Dermira?

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]


This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.